Global and United States Antitumor Drugs of Antimetabolite Class In-Depth Research Report 2017-2022

August 2017 | 111 pages | ID: G4CB33E72A3EN
US Market Insights (UMI)

Abstracts

The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022.

This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Antitumor Drugs of Antimetabolite Class industry.

Major Companies

• ABON PHARMS LLC
• BARR
• CELATOR PHARMA INC
• DR REDDYS LABS LTD
• EUROHLTH INTL
• FRESENIUS KABI USA
• GENZYME
• LILLY
• MERCK SHARP DOHME
• MYLAN LABS LTD
• NOVARTIS PHARMS CORP
• PACIRA PHARMS INC
• PIERRE FABRE
• SAGENT PHARMS
• SANDOZ
• TEVA PARENTERAL
• WEST-WARD PHARMS INT
• ZYDUS PHARMS USA INC

Key Regions

• North America
• United States
• California
• Texas
• New York
• Others
• Canada
• Latin America
• Mexico
• Brazil
• Argentina
• Others
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Russia
• Netherland
• Others
• Asia & Pacific
• China
• Japan
• India
• Korea
• Australia
• Southeast Asia
• Indonesia
• Thailand
• Philippines
• Vietnam
• Singapore
• Malaysia
• Others
• Africa & Middle East
• South Africa
• Egypt
• Turkey
• Saudi Arabia
• Iran
• Others

Main types of products

Antitumor Drugs of Antimetabolite Class Market, by Antimetabolite Class

• Gemcitabine
• Doxifluridine
• Methotrexate
• Cytarabine
• Fludarabine
• Vinorelbine
• Temozolomide
• Clofarabine
• Arranon
• Ciclosporin
• Tegafur
• Aminopterin

Antitumor Drugs of Antimetabolite Class Market, by Key Consumers

• Oncology Department
• Department of Chemotherapy
• Pharmacology

Contents

CHAPTER ONE GLOBAL ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS MARKET OVERVIEW

1.1 Global Antitumor Drugs of Antimetabolite Class Market Sales Volume Revenue and Price 2012-2017
1.2 Antitumor Drugs of Antimetabolite Class, by Antimetabolite Class 2012-2017
  1.2.1 Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class 2012-2017
  1.2.2 Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class 2012-2017
  1.2.3 Global Antitumor Drugs of Antimetabolite Class Price by Antimetabolite Class 2012-2017
  1.2.4 Gemcitabine
  1.2.5 Doxifluridine
  1.2.6 Methotrexate
  1.2.7 Cytarabine
  1.2.8 Fludarabine
Vinorelbine
Temozolomide
Clofarabine
Arranon
Ciclosporin
Tegafur
Aminopterin

CHAPTER TWO UNITED STATES ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS MARKET OVERVIEW

2.1 United States Antitumor Drugs of Antimetabolite Class Market Sales Volume Revenue and Price 2012-2017
2.2 Antitumor Drugs of Antimetabolite Class, by Antimetabolite Class 2012-2017
  2.2.1 United States Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class 2012-2017
  2.2.2 United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class 2012-2017
  2.2.3 United States Antitumor Drugs of Antimetabolite Class Price by Antimetabolite Class 2012-2017
  2.2.4 Gemcitabine
  2.2.5 Doxifluridine
  2.2.6 Methotrexate
  2.2.7 Cytarabine
  2.2.8 Fludarabine
Vinorelbine
Temozolomide
Clofarabine
Arranon
Ciclosporin
Tegafur
Aminopterin

CHAPTER THREE ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS BY REGIONS 2012-2017

3.1 Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Regions 2012-2017
3.2 Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Regions 2012-2017
3.3 Global Antitumor Drugs of Antimetabolite Class Price by Regions 2012-2017
3.4 North America
  3.4.1 United States
    3.4.1.1 California
    3.4.1.2 Texas
    3.4.1.3 New York
    3.4.1.4 Others in United States
  3.4.2 Canada
3.5 Latin America
  3.5.1 Mexico
  3.5.2 Brazil
  3.5.3 Argentina
  3.5.4 Others in Latin America
3.6 Europe
  3.6.1 Germany
  3.6.2 United Kingdom
  3.6.3 France
  3.6.4 Italy
  3.6.5 Spain
  3.6.6 Russia
  3.6.7 Netherland
  3.6.8 Others in Europe
3.7 Asia & Pacific
  3.7.1 China
  3.7.2 Japan
  3.7.3 India
  3.7.4 Korea
  3.7.5 Australia
  3.7.6 Southeast Asia
    3.7.6.1 Indonesia
    3.7.6.2 Thailand
    3.7.6.3 Philippines
    3.7.6.4 Vietnam
    3.7.6.5 Singapore
    3.7.6.6 Malaysia
    3.7.6.7 Others in Southeast Asia
3.8 Africa & Middle East
  3.8.1 South Africa
  3.8.2 Egypt
  3.8.3 Turkey
  3.8.4 Saudi Arabia
  3.8.5 Iran
  3.8.6 Others in Africa & Middle East

CHAPTER FOUR GLOBAL ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS BY COMPANIES 2012-2017

4.1 Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Companies 2012-2017
4.2 Global Antitumor Drugs of Antimetabolite Class Revenue Share by Companies 2012-2017
4.3 Global Top Companies Antitumor Drugs of Antimetabolite Class Key Product Model and Market Performance
4.4 Global Top Companies Antitumor Drugs of Antimetabolite Class Key Target Consumers and Market Performance

CHAPTER FIVE UNITED STATES ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS BY COMPANIES 2012-2017

5.1 United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Companies 2012-2017
5.2 United States Antitumor Drugs of Antimetabolite Class Revenue Share by Companies 2012-2017
5.3 United States Top Companies Antitumor Drugs of Antimetabolite Class Key Product Model and Market Performance
5.4 United States Top Companies Antitumor Drugs of Antimetabolite Class Key Target Consumers and Market Performance

CHAPTER SIX GLOBAL ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS BY CONSUMER 2012-2017

6.1 Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Consumer 2012-2017
6.2 Oncology Department
6.3 Department of Chemotherapy
6.4 Pharmacology
6.5 Consuming Habit and Preference

CHAPTER SEVEN GLOBAL ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS BY CONSUMER 2012-2017

7.1 Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Consumer 2012-2017
7.2 Oncology Department
7.3 Department of Chemotherapy
7.4 Pharmacology
7.5 Consuming Habit and Preference

CHAPTER EIGHT TOP COMPANIES PROFILE

8.1 ABON PHARMS LLC
  8.1.1 ABON PHARMS LLC Company Details and Competitors
  8.1.2 ABON PHARMS LLC Key Antitumor Drugs of Antimetabolite Class Models and Performance
  8.1.3 ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
  8.1.4 ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin
8.2 BARR
  8.2.1 BARR Company Details and Competitors
  8.2.2 BARR Key Antitumor Drugs of Antimetabolite Class Models and Performance
  8.2.3 BARR Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
  8.2.4 BARR Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin
8.3 CELATOR PHARMA INC
  8.3.1 CELATOR PHARMA INC Company Details and Competitors
  8.3.2 CELATOR PHARMA INC Key Antitumor Drugs of Antimetabolite Class Models and Performance
  8.3.3 CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
  8.3.4 CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin
8.4 DR REDDYS LABS LTD
  8.4.1 DR REDDYS LABS LTD Company Details and Competitors
  8.4.2 DR REDDYS LABS LTD Key Antitumor Drugs of Antimetabolite Class Models and Performance
  8.4.3 DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
  8.4.4 DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin
8.5 EUROHLTH INTL
  8.5.1 EUROHLTH INTL Company Details and Competitors
  8.5.2 EUROHLTH INTL Key Antitumor Drugs of Antimetabolite Class Models and Performance
  8.5.3 EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
  8.5.4 EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin
8.6 FRESENIUS KABI USA
  8.6.1 FRESENIUS KABI USA Company Details and Competitors
  8.6.2 FRESENIUS KABI USA Key Antitumor Drugs of Antimetabolite Class Models and Performance
  8.6.3 FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
  8.6.4 FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin
8.7 GENZYME
  8.7.1 GENZYME Company Details and Competitors
  8.7.2 GENZYME Key Antitumor Drugs of Antimetabolite Class Models and Performance
  8.7.3 GENZYME Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
  8.7.4 GENZYME Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin
8.8 LILLY
  8.8.1 LILLY Company Details and Competitors
  8.8.2 LILLY Key Antitumor Drugs of Antimetabolite Class Models and Performance
  8.8.3 LILLY Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
  8.8.4 LILLY Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin
8.9 MERCK SHARP DOHME
  8.9.1 MERCK SHARP DOHME Company Details and Competitors
  8.9.2 MERCK SHARP DOHME Key Antitumor Drugs of Antimetabolite Class Models and Performance
  8.9.3 MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
  8.9.4 MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin
8.10 MYLAN LABS LTD
  8.10.1 MYLAN LABS LTD Company Details and Competitors
  8.10.2 MYLAN LABS LTD Key Antitumor Drugs of Antimetabolite Class Models and Performance
  8.10.3 MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
  8.10.4 MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Sales Volume Revenue Price Cost and Gross Margin
8.11 NOVARTIS PHARMS CORP
8.12 PACIRA PHARMS INC
8.13 PIERRE FABRE
8.14 SAGENT PHARMS
8.15 SANDOZ
8.16 TEVA PARENTERAL
8.17 WEST-WARD PHARMS INT
8.18 ZYDUS PHARMS USA INC

CHAPTER NINE INDUSTRY CHAIN AND SUPPLY CHAIN

9.1 Antitumor Drugs of Antimetabolite Class Industry Chain Structure
  9.1.1 R&D
  9.1.2 Raw Materials (Components)
  9.1.3 Manufacturing Plants
  9.1.4 Regional Trading (Import Export and Local Sales)
  9.1.5 Online Sales Channel
  9.1.6 Offline Channel
  9.1.7 End Users
9.2 Antitumor Drugs of Antimetabolite Class Manufacturing
  9.2.1 Key Components
  9.2.2 Assembly Manufacturing
9.3 Consumer Preference
9.4 Behavioral Habits
9.5 Marketing Environment

CHAPTER TEN GLOBAL ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

10.1 Global Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD) Forecast (2017-2022)
10.2 Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)
10.3 Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)
10.4 Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Antimetabolite Class (2017-2022)
10.5 Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by (2017-2022)

CHAPTER ELEVEN UNITED STATES ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

11.1 United States Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD) Forecast (2017-2022)
11.2 United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)
11.3 United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)
11.4 United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by Antimetabolite Class (2017-2022)
11.5 United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by (2017-2022)

CHAPTER TWELVE DEVELOPMENT TREND AND RESEARCH CONCLUSION

12.1 Development Trend
12.2 Research Conclusion

CHAPTER THIRTEEN METHODOLOGY AND DATA SOURCE

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Table Global Antitumor Drugs of Antimetabolite Class Sales Volume (), Revenue (Million USD) and Price ()(2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate (2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume () and Growth Rate (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Sales () by Antimetabolite Class (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class (2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class in 2016
Table Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Antimetabolite Class (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class (2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class in 2016
Table Global Antitumor Drugs of Antimetabolite Class Price () by Antimetabolite Class (2012-2017)
Table Top Companies of Gemcitabine Antitumor Drugs of Antimetabolite Class Products List
Figure Global Gemcitabine Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Doxifluridine Antitumor Drugs of Antimetabolite Class Products List
Figure Global Doxifluridine Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Methotrexate Antitumor Drugs of Antimetabolite Class Products List
Figure Global Methotrexate Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Cytarabine Antitumor Drugs of Antimetabolite Class Products List
Figure Global Cytarabine Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Fludarabine Antitumor Drugs of Antimetabolite Class Products List
Figure Global Fludarabine Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Sales () by (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Sales Market Share by (2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by in 2016
Table Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by (2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by in 2016
Table Global Antitumor Drugs of Antimetabolite Class Price () by (2012-2017)
Figure United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate (2012-2017)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume () and Growth Rate (2012-2017)
Table United States Antitumor Drugs of Antimetabolite Class Sales () by Antimetabolite Class (2012-2017)
Table United States Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class (2012-2017)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Market Share by Antimetabolite Class in 2016
Table United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Antimetabolite Class (2012-2017)
Table United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class (2012-2017)
Figure United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Antimetabolite Class in 2016
Table United States Antitumor Drugs of Antimetabolite Class Price () by Antimetabolite Class (2012-2017)
Table Top Companies of Gemcitabine Antitumor Drugs of Antimetabolite Class Products List
Figure United States Gemcitabine Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Doxifluridine Antitumor Drugs of Antimetabolite Class Products List
Figure United States Doxifluridine Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Methotrexate Antitumor Drugs of Antimetabolite Class Products List
Figure United States Methotrexate Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Cytarabine Antitumor Drugs of Antimetabolite Class Products List
Figure United States Cytarabine Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Top Companies of Fludarabine Antitumor Drugs of Antimetabolite Class Products List
Figure United States Fludarabine Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table United States Antitumor Drugs of Antimetabolite Class Sales () by (2012-2017)
Table United States Antitumor Drugs of Antimetabolite Class Sales Market Share by (2012-2017)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Market Share by in 2016
Table United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by (2012-2017)
Table United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by (2012-2017)
Figure United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by in 2016
Table United States Antitumor Drugs of Antimetabolite Class Price () by (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Sales () by Regions (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Sales Share by Regions (2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Regions in 2016
Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Regions in 2017
Table Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share by Regions (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Regions (2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Regions in 2016
Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Regions in 2017
Table Global Antitumor Drugs of Antimetabolite Class Price () by Regions (2012-2017)
Table North America Antitumor Drugs of Antimetabolite Class Sales () by Regions (2012-2017)
Table North America Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)
Figure North America Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table United States Antitumor Drugs of Antimetabolite Class Sales () by Regions (2012-2017)
Table United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)
Figure United States Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Latin America Antitumor Drugs of Antimetabolite Class Sales () by Regions (2012-2017)
Table Latin America Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)
Figure Latin America Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Europe Antitumor Drugs of Antimetabolite Class Sales () by Regions (2012-2017)
Table Europe Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)
Figure Europe Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Asia & Pacific Antitumor Drugs of Antimetabolite Class Sales () by Regions (2012-2017)
Table Asia & Pacific Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)
Figure Asia & Pacific Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Africa & Middle East Antitumor Drugs of Antimetabolite Class Sales () by Regions (2012-2017)
Table Africa & Middle East Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Regions (2012-2017)
Figure Africa & Middle East Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Sales Volume () by Major Companies (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Major Companies (2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Major Companies 2016
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Major Companies 2017
Table Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Major Companies (2012-2017)
Table Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Major Companies (2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Major Companies 2016
Figure Global Antitumor Drugs of Antimetabolite Class Revenue Market Share by Major Companies 2017
Table Global Top Companies Key Product Model and Market Performance
Table Global Top Companies Key Target Consumers and Market Performance
Table United States Antitumor Drugs of Antimetabolite Class Sales Volume () by Top Companies (2012-2017)
Table United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Top Companies (2012-2017)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Top Companies 2016
Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share by Top Companies 2017
Table United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) by Top Companies (2012-2017)
Table United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Top Companies (2012-2017)
Figure United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Top Companies 2016
Figure United States Antitumor Drugs of Antimetabolite Class Revenue Market Share by Top Companies 2017
Table United States Top Companies Key Product Model and Market Performance
Table United States Top Companies Key Target Consumers and Market Performance
Table Global Antitumor Drugs of Antimetabolite Class Sales () by Consumer (2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Consumer (2012-2017)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Market Share by Consumer in 2016
Figure Global Oncology Department Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Figure Global Department of Chemotherapy Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Figure Global Pharmacology Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table United States Antitumor Drugs of Antimetabolite Class Sales () by Consumer (2012-2017)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Market Share by Consumer (2012-2017)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Market Share by Consumer in 2016
Figure United States Oncology Department Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Figure United States Department of Chemotherapy Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Figure United States Pharmacology Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (2012-2017)
Table ABON PHARMS LLC Company Details and Competitors
Table ABON PHARMS LLC Key Antitumor Drugs of Antimetabolite Class Models and Performance
Table ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
Table ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)
Figure ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure ABON PHARMS LLC Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)
Table BARR Company Details and Competitors
Table BARR Key Antitumor Drugs of Antimetabolite Class Models and Performance
Table BARR Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
Table BARR Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure BARR Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure BARR Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)
Figure BARR Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure BARR Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)
Table CELATOR PHARMA INC Company Details and Competitors
Table CELATOR PHARMA INC Key Antitumor Drugs of Antimetabolite Class Models and Performance
Table CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
Table CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)
Figure CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure CELATOR PHARMA INC Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)
Table DR REDDYS LABS LTD Company Details and Competitors
Table DR REDDYS LABS LTD Key Antitumor Drugs of Antimetabolite Class Models and Performance
Table DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
Table DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)
Figure DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure DR REDDYS LABS LTD Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)
Table EUROHLTH INTL Company Details and Competitors
Table EUROHLTH INTL Key Antitumor Drugs of Antimetabolite Class Models and Performance
Table EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
Table EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)
Figure EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure EUROHLTH INTL Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)
Table FRESENIUS KABI USA Company Details and Competitors
Table FRESENIUS KABI USA Key Antitumor Drugs of Antimetabolite Class Models and Performance
Table FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
Table FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)
Figure FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure FRESENIUS KABI USA Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)
Table GENZYME Company Details and Competitors
Table GENZYME Key Antitumor Drugs of Antimetabolite Class Models and Performance
Table GENZYME Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
Table GENZYME Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure GENZYME Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure GENZYME Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)
Figure GENZYME Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure GENZYME Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)
Table LILLY Company Details and Competitors
Table LILLY Key Antitumor Drugs of Antimetabolite Class Models and Performance
Table LILLY Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
Table LILLY Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure LILLY Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure LILLY Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)
Figure LILLY Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure LILLY Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)
Table MERCK SHARP DOHME Company Details and Competitors
Table MERCK SHARP DOHME Key Antitumor Drugs of Antimetabolite Class Models and Performance
Table MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
Table MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)
Figure MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure MERCK SHARP DOHME Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)
Table MYLAN LABS LTD Company Details and Competitors
Table MYLAN LABS LTD Key Antitumor Drugs of Antimetabolite Class Models and Performance
Table MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Business SWOT Analysis and Forecast
Table MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Output (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Figure MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Sales (Million Unit) and Growth Rate (%)(2012-2017)
Figure MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Global (2012-2017)
Figure MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Sales Revenue (Million USD) and Growth Rate (%)(2012-2017)
Figure MYLAN LABS LTD Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Global (2012-2017)
Table NOVARTIS PHARMS CORP Company Details and Competitors
Table PACIRA PHARMS INC Company Details and Competitors
Table PIERRE FABRE Company Details and Competitors
Table SAGENT PHARMS Company Details and Competitors
Table SANDOZ Company Details and Competitors
Table TEVA PARENTERAL Company Details and Competitors
Table WEST-WARD PHARMS INT Company Details and Competitors
Table ZYDUS PHARMS USA INC Company Details and Competitors
Figure Global Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (%) Forecast (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Price () Trend Forecast (2017-2022)
Table Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)
Table Global Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions in 2022
Table Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application in 2022
Table Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Antimetabolite Class (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Antimetabolite Class (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Antimetabolite Class in 2022
Table Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by (2017-2022)
Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by in 2022
Figure United States Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (%) Forecast (2017-2022)
Figure United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Antitumor Drugs of Antimetabolite Class Price () Trend Forecast (2017-2022)
Table United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)
Table United States Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions in 2022
Table United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application (2017-2022)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application in 2022
Table United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by Antimetabolite Class (2017-2022)
Figure United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by Antimetabolite Class (2017-2022)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Antimetabolite Class in 2022
Table United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by (2017-2022)
Figure United States Antitumor Drugs of Antimetabolite Class Sales () Forecast by (2017-2022)
Figure United States Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by in 2022